Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy

Figure 2

Significant OS difference between high-expression and low-expression groups of SRSF9 in ACC, KIRP, LGG, LIHC, LUAD, THYM, and UVM and the association between SRSF9 expression levels with OS in pan-cancer.